Clinical trials: Indolent Lymphoma
Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
- Conditions
- Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
- Trial name
- NCT00060684
- Testing
- Pixantrone (BBR 2778), fludarabine, dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- CTI BioPharma
Lymphoma, Non-Hodgkin
Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the second line therapy of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma
- Trial name
- NCT02072967
- Testing
- Ribomustin, rituximab
- Where
- 35 sites in Russia
- Volunteers
- 97 people
- Sponsor
- Astellas Pharma Europe B.V.